Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P20823: Variant p.Ser142Phe

Hepatocyte nuclear factor 1-alpha
Gene: HNF1A
Feedback?
Variant information Variant position: help 142 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Serine (S) to Phenylalanine (F) at position 142 (S142F, p.Ser142Phe). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and polar (S) to large size and aromatic (F) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In MODY3; reduces transcription activation by about 80%. Any additional useful information about the variant.


Sequence information Variant position: help 142 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 631 The length of the canonical sequence.
Location on the sequence: help YLQQHNIPQREVVDTTGLNQ S HLSQHLNKGTPMKTQKRAAL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         YLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAAL

Mouse                         YLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAAL

Rat                           YLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAAL

Chicken                       YLQQHNIPQREVVDTTGLNQSHLSQHLNKGTPMKTQKRAAL

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 631 Hepatocyte nuclear factor 1-alpha
Domain 87 – 182 POU-specific atypical
Alternative sequence 120 – 631 Missing. In isoform 8.
Mutagenesis 127 – 127 N -> W. Abolishes transcription activation.
Mutagenesis 132 – 132 E -> K. Abolishes transcription activation.
Helix 141 – 149



Literature citations
Diabetes mutations delineate an atypical POU domain in HNF-1alpha.
Chi Y.I.; Frantz J.D.; Oh B.C.; Hansen L.; Dhe-Paganon S.; Shoelson S.E.;
Mol. Cell 10:1129-1137(2002)
Cited for: X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 85-278 IN COMPLEX WITH DNA; FUNCTION; DNA-BINDING; MUTAGENESIS OF ASN-127; GLU-132; PHE-177; ILE-186; THR-190; ASN-202; VAL-246 AND ASN-257; CHARACTERIZATION OF VARIANTS MODY3 PHE-142 AND GLN-205; Identification of nine novel mutations in the hepatocyte nuclear factor 1 alpha gene associated with maturity-onset diabetes of the young (MODY3).
Vaxillaire M.; Rouard M.; Yamagata K.; Oda N.; Kaisaki P.J.; Boriraj V.V.; Chevre J.-C.; Boccio V.; Cox R.D.; Lathrop G.M.; Dussoix P.; Philippe J.; Timsit J.; Charpentier G.; Velho G.; Bell G.I.; Froguel P.;
Hum. Mol. Genet. 6:583-586(1997)
Cited for: VARIANTS MODY3 CYS-122; PHE-142 AND GLN-159;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.